Maynard Um
-
-
-
-
-
-
-
CRISPR Therapeutics (CRSP) Misses Q4 EPS by 20c
-
-
-
-
-
-
-
CRISPR Therapeutics (CRSP) call put ratio 6.5 calls to 1 put with a focus November 55 and 65 calls
-
-
-
-
-
-
-
CRISPR Therapeutics (CRSP) Tops Q3 EPS by 9c
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on CRISPR Therapeutics (CRSP)
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on CRISPR Therapeutics (CRSP)
-
-
-
-
-
-
-
William Blair Reiterates Outperform Rating on CRISPR Therapeutics (CRSP)
-
-
-
-
-
-
-
CRISPR Therapeutics (CRSP) and Sirius Therapeutics Announce Multi-Target Collaboration to Develop Novel siRNA Therapies
-
404,029 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

